Cure8 news brief
Mucosal colonisation by adherent‑invasive E. coli has been implicated in Crohn’s disease for some patients; this study suggests FMT can change the mucosal microbiome and clear AIEC in a small pilot cohort, which could be relevant for microbiome‑targeted therapies.
Adults with Crohn’s disease, clinicians and researchers interested in microbiome therapies, and people following FMT research
This was an open‑label pilot study of 30 adults with Crohn’s disease who were seropositive for anti‑E. coli antibody; 30 received a single colonoscopic FMT from one of two donors. The primary outcome was safety (adverse events at 12 weeks); no serious FMT‑related adverse events were reported.
Among the eight patients who had mucosal AIEC at baseline and were evaluable, all showed mucosal AIEC decolonisation after FMT. Mucosal alpha‑diversity increased post‑FMT and this change correlated with reduced fecal calprotectin.
Metagenomic and 16S sequencing showed recipient mucosal microbial pathway profiles became more similar to donors, especially in those who decolonised.
The study shows feasibility of using FMT to alter mucosal microbiota and clear mucosal AIEC in a small, selected group, but it was not designed to prove causality or clinical benefit beyond microbiologic and biomarker changes. Larger, controlled trials are needed to confirm efficacy, durability, and clinical impact.
This was an open‑label pilot study with a small number of evaluable AIEC‑positive patients; findings are early and hypothesis‑generating. The report focuses on microbiologic and biomarker changes rather than definitive clinical outcomes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
